DLPIC
IOVA icon

Davide Leone & Partners Investment Company’s Iovance Biotherapeutics IOVA Stock Holding History

Davide Leone & Partners Investment Company’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-53,267
Closed -$1.69M – 89
2021
Q1 		$1.69M Buy
53,267
+18,582
+54% +$770K 0.21% 68
2020
Q4 		$1.61M Buy
+34,685
New +$1.38M 0.17% 67

Other funds holding IOVA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Davide Leone & Partners Investment Company's IOVA Position: Q2 2021 in Review

Davide Leone & Partners Investment Company sold out of Iovance Biotherapeutics (IOVA) in Q2 2021, closing a stake of 53,267 shares — an estimated $1.69M sold.

Davide Leone & Partners Investment Company first reported a position in IOVA in Q4 2020 and held it in 2 quarters. The position peaked at $1.69M in Q1 2021. 233 funds tracked by Wall St. Rank hold IOVA as of Q2 2021.

  • Davide Leone & Partners Investment Company reported no remaining Iovance Biotherapeutics position as of Q2 2021 after selling out during the quarter.
  • Davide Leone & Partners Investment Company sold 53,267 Iovance Biotherapeutics shares in Q2 2021, an estimated $1.69M.
  • Davide Leone & Partners Investment Company first reported a position in Iovance Biotherapeutics in Q4 2020 and held it in 2 quarters.
  • Davide Leone & Partners Investment Company's Iovance Biotherapeutics position peaked at $1.69M in Q1 2021.
  • 233 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2021.

Based on Davide Leone & Partners Investment Company's 13F filing for Q2 2021, filed 16 Aug 2021.